COMP NEWS – Pfizer has agreed to pay $2 million as part of a settlement for a case where the biopharmaceutical company was accused of underpaying women compared to their male counterparts.

Pfizer will pay $2 million as part of a conciliation agreement with the U.S. Department of Labor’s Office of Federal Contract Compliance Programs to resolve pay discrimination allegations, the agency announced Monday.

Per the agreement, OFCCP conducted a compliance review of Pfizer covering the period between 2015 and 2016 and allegedly found that the pharmaceutical company discriminated against 86 women by paying them less than comparable male employees.

As a result, OFCCP alleged that Pfizer violated Executive Order 11246, which prohibits federal contractors from discriminating in employment decisions on the basis of protected characteristics including race, color, religion, sex, sexual orientation, gender identity and national origin.

In an email to HR Dive, Pfizer said that the agency’s audit “involved minor pay discrepancies from over seven years ago among a small group of employees at a single location.”

The payout includes the total amount of back pay to undercompensated employees along with more than $700,000 in interest.

The $2 million total payout includes more than $1.2 million in back pay to the affected employees along with more than $737,000 in interest. Pfizer agreed to immediately cease using discriminatory compensation practices and implement training for individuals involved in determining compensation for the affected job titles, among other items.

Monday’s announcement represents one of several pay discrimination enforcement actions taken by OFCCP under the Biden administration. Agency Director Jenny Yang identified pay equity as a top focus for OFCCP in 2021, and in the time since, it has inked conciliation agreements with employers such as Pfizer, JPMorgan Chase & Co. and Microsoft-owned LinkedIn.

To read more about Pfizer’s payout, click here.

For more Comp News, see our recent posts.